[go: up one dir, main page]

MX2021002792A - Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos. - Google Patents

Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.

Info

Publication number
MX2021002792A
MX2021002792A MX2021002792A MX2021002792A MX2021002792A MX 2021002792 A MX2021002792 A MX 2021002792A MX 2021002792 A MX2021002792 A MX 2021002792A MX 2021002792 A MX2021002792 A MX 2021002792A MX 2021002792 A MX2021002792 A MX 2021002792A
Authority
MX
Mexico
Prior art keywords
antibody composition
igg1 antibody
glycosylated
afucosylated
methods
Prior art date
Application number
MX2021002792A
Other languages
English (en)
Inventor
Alla Polozova
Qingchun Zhang
Scott Kuhns
Dong Xiang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2021002792A publication Critical patent/MX2021002792A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona un método para controlar la actividad de Citotoxicidad Celular Dependiente de Anticuerpos (ADCC) de una composición de anticuerpos IgG1 glucosilados y afucosilados. En realizaciones de ejemplo, el método incluye (1) determinar la actividad ADCC de una composición de anticuerpos IgG1 glucosilados y afucosilados; y (2) aumentar o disminuir la actividad ADCC de la composición de anticuerpos IgG1 aumentando o disminuyendo la cantidad de ß-galactosa terminal en la especie de glucano afucosilado en el sitio de glucosilación consenso. En el presente documento también se proporcionan métodos relacionados para igualar la actividad ADCC de una composición de anticuerpos IgG1 glucosilados y afucosilados de referencia y métodos para diseñar por ingeniería una actividad ADCC diana específica de una composición de anticuerpos IgG1 glucosilados y afucosilados.
MX2021002792A 2018-09-11 2019-09-10 Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos. MX2021002792A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862729971P 2018-09-11 2018-09-11
PCT/US2019/050459 WO2020055900A1 (en) 2018-09-11 2019-09-10 Methods of modulating antibody-dependent cell-mediated cytotoxicity

Publications (1)

Publication Number Publication Date
MX2021002792A true MX2021002792A (es) 2021-05-12

Family

ID=68051968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002792A MX2021002792A (es) 2018-09-11 2019-09-10 Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.

Country Status (8)

Country Link
US (1) US20220033511A1 (es)
EP (1) EP3850006A1 (es)
JP (2) JP2022500371A (es)
AU (1) AU2019339895A1 (es)
CA (1) CA3110530A1 (es)
MA (1) MA53603A (es)
MX (1) MX2021002792A (es)
WO (1) WO2020055900A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230147658A (ko) * 2021-02-19 2023-10-23 제넨테크, 인크. 데이터 모델링에서 관련 생물물리학적 속성에 기초한 기능 예측 방법 및 시스템
WO2022200390A2 (en) * 2021-03-23 2022-09-29 Glycoera Ag Glycan-mediated protein degradation
WO2024220916A1 (en) * 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
EP2506868B1 (en) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
HUE044419T2 (hu) 2010-07-09 2019-10-28 Bioverativ Therapeutics Inc Feldogozható egyetlen láncú molekulák és ezek alkalmazásával készült peptidek
WO2013114167A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Process of obtaining glycoform composition
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
WO2015128793A1 (en) 2014-02-25 2015-09-03 Dr. Reddy’S Laboratories Limited A process for modifying high mannose and galactosylation content of a glycoprotein composition
WO2015140700A1 (en) 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
AU2015267047A1 (en) * 2014-05-27 2017-01-05 Academia Sinica Anti-CD20 glycoantibodies and uses thereof
JP2017528468A (ja) * 2014-09-10 2017-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ガラクトース操作型免疫グロブリン１抗体
EA036178B1 (ru) 2014-12-01 2020-10-09 Эмджен Инк. Процесс контроля уровня содержания гликанов в составе гликопротеинов
EP3925970A1 (en) 2015-11-02 2021-12-22 F. Hoffmann-La Roche AG Methods of making fucosylated and afucosylated forms of a protein
WO2017134667A1 (en) 2016-02-02 2017-08-10 Insight Biopharmaceuticals Ltd. Methods of generating antibodies

Also Published As

Publication number Publication date
AU2019339895A1 (en) 2021-03-11
US20220033511A1 (en) 2022-02-03
CA3110530A1 (en) 2020-03-19
EP3850006A1 (en) 2021-07-21
WO2020055900A1 (en) 2020-03-19
JP2024112905A (ja) 2024-08-21
JP2022500371A (ja) 2022-01-04
MA53603A (fr) 2021-07-21

Similar Documents

Publication Publication Date Title
MX2021002792A (es) Metodos para modular la citotoxicidad mediada por celulas dependiente de anticuerpos.
NZ766968A (en) Anti-cd73 antibodies and uses thereof
ZA202106516B (en) Rna-guided dna integration using tn7-like transposons
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MY205672A (en) Anti-phf-tau antibodies and uses thereof
ZA202208710B (en) Anti-vegf protein compositions and methods for producing the same
MXPA04004809A (es) Conjugados de hormona de crecimiento humana modificada quimicamente.
WO2020139926A3 (en) Anti-ctla4 antibodies and methods of use thereof
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
EP3968421A4 (en) RADICAL SCAVER, METHOD FOR ITS PRODUCTION AND MEMBRANE-ELECTRODE UNIT THEREOF
WO2022082073A3 (en) Compositions and methods for muc18 targeting
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
EP4462121A3 (en) Recombinant glycosylated eculizumab and eculizumab variants
PH12022553035A1 (en) Anti-phf-tau antibodies and uses thereof
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
MX2021008760A (es) Anticuerpo anti-cd79b, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2021001521A (es) Estrategias de cultivo celular para modular la glucosilacion de proteinas.
MX2022007513A (es) Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos.
MX2020013772A (es) Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
EP4026906A4 (en) COMPOSITION FOR TRANSLATION AND METHOD FOR PRODUCING PEPTIDES
WO2020234205A3 (de) Verfahren zur herstellung eines leitfähigen pflanzlichen materials, leitfähiges pflanzliches material und verwendung